Skip to content
Menu

Actuate Therapeutics Announces Preclinical Data Demonstrating That Daily Oral Administration Of Elraglusib Achieved Up To 77% Tumor Growth Inhibition As Monotherapy In An Aggressive Melanoma Model

Benzinga Newsdesk 4 hours ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Daily oral elraglusib achieved up to 77% tumor growth inhibition as monotherapy in an aggressive preclinical melanoma model, with greater antitumor activity observed at higher drug exposures
Treatment was associated with changes in the tumor immune microenvironment, characterized by increased cytotoxic T cells and natural killer cells and reduced immunosuppressive myeloid cells
Findings further reinforce initiation of Phase 1/2 clinical trial in Q1 2027 with daily dosing of elraglusib oral tablet

Read at benzinga.com